Abstract:FXS is the most common genetic cause of intellectual (ID) and autism spectrum disorders (ASD). FXS is caused by loss of FMRP, an RNA-binding protein involved in the translational regulation of a large number of neuronal mRNAs. Absence of FMRP has been shown to lead to elevated protein synthesis and is thought to be a major cause of the synaptic plasticity and behavioural deficits in FXS. The increase in protein synthesis results in part from abnormal activation of key protein translation pathways downstream of ERK1/2 and mTOR signalling. Pharmacological and genetic interventions that attenuate hyperactivation of these pathways can normalize levels of protein synthesis and improve phenotypic outcomes in animal models of FXS. Several efforts are currently underway to trial this strategy in patients with FXS. To date, elevated global protein synthesis as a result of FMRP loss has not been validated in the context of human neurons. Here, using an isogenic human stem cell-based model, we show that de novo protein synthesis is elevated in FMRP-deficient neural cells. We further show that this increase is associated with elevated ERK1/2 and Akt signalling and can be rescued by metformin treatment. Finally, we examined the effect of normalizing protein synthesis on phenotypic abnormalities in FMRP-deficient neural cells. We find that treatment with metformin attenuates the increase in proliferation of FMRP-deficient neural progenitor cells but not the neuronal deficits in neurite outgrowth. The elevated level of protein synthesis and the normalization of neural progenitor proliferation by metformin treatment were validated in additional control and FXS patient-derived hiPSC lines. Overall, our results validate that loss of FMRP results in elevated de novo protein synthesis in human neurons and suggest that approaches targeting this abnormality are likely to be of partial therapeutic benefit in FXS.

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases

Metformin treatment in young children with fragile X syndrome

Metformin as targeted treatment in fragile X syndrome

The safety and efficacy of metformin in fragile X syndrome: An open-label study

Longitudinal follow-up of metformin treatment in Fragile X Syndrome

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders

Metformin ameliorates core deficits in a mouse model of fragile X syndrome

A therapy for FXS?

State‐of‐the‐art therapies for fragile X syndrome

Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model

New Targeted Treatments for Fragile X Syndrome

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Targeted Treatments for Fragile X Syndrome

Effects of a combined neuropsychological and cognitive behavioral group therapy on young adults with Fragile X Syndrome: An explorative study

Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model

Metformin Improves Cognition of Aged Mice by Promoting Cerebral Angiogenesis and Neurogenesis

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment

Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment

Cognition, academic achievement, and adaptive behavior in school-aged girls with fragile X syndrome

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder